Verge Genomics Halts Clinical Development of AI-Discovered ALS Drug VRG50635 Amid Leadership Overhaul

Recently, AI pharmaceutical companiesVerge GenomicsAnnounced the Termination of Its AI Drug Candidate Entering Clinical StageVRG50635The development was terminated due to "lack of risk-benefit data."

Verge Genomics was founded in 2015 and has quickly risen to become a star company in the AI pharmaceuticals field with its unique CONVERGE end-to-end drug discovery platform. The core advantage of this platform lies inDirectly Using Patient Brain Tissue for Research, rather than traditional animal models, by analyzing large-scale human multimodal datasets to identify disease targets.

This technical advantageHas attracted the favor of pharmaceutical giantsIn July 2021, Verge Genomics entered into a nearly $700 million ALS drug development collaboration with Eli Lilly, receiving a $25 million upfront payment. In September 2023, AstraZeneca invested $42 million to establish a research and development collaboration with Verge Genomics. Within just a few years, Verge Genomics has raised over $130 million in cumulative financing, with its valuation reaching $750 million at one point, and was named to the Fierce 15 list in 2022.

VRG50635, as a PIKfyve inhibitor discovered by the company using the CONVERGE platform, aims to treat Amyotrophic Lateral Sclerosis (ALS, commonly known asAmyotrophic Lateral Sclerosis (ALS)), but recently, its efficacy in Phase 1b clinical trials for patients with amyotrophic lateral sclerosis did not meet the standard, and the clinical trial has been terminated.

Amyotrophic lateral sclerosis is known as one of the most daunting challenges in the field of neuroscience. In the past two decades, at least dozens of clinical trials for ALS therapies have failed to show positive results, and Verge's setback is yet another confirmation of this.The High Risk of Central Nervous System Drug Development.

As the drug failed, Verge Genomics was undergoing a major management overhaul. Over the past 20 months, most of the company's senior executives have left, including the Chief Financial Officer, Chief Scientific Officer, and Chief Medical Officer. President and Chief Business Officer Jane Rhodes also departed last year to become the CEO of neurobiotechnology company AstronauTx.

Verge Genomics Partial Pipeline

Source of the image: Pharma Data - Global Drug Analysis System

ConclusionIn the "nine deaths, one life" field of drug research and development, no technology can bypass the fundamental laws of biology. However, the vast amount of data accumulated by AI and innovations in methodology are still paving the way for the next generation of drug discovery. How to balance technological innovation with clinical reality, and how to shift from a high-risk model to a sustainable path, will determine which companies can truly navigate through cycles and become the ultimate winners in the industry.

Reference Source:

1. PharmaGo Data - Global Drug Analysis System

2.https://mp.weixin.qq.com/s/mgspSM_uArAZ00NdgjsLdw

Editorial Responsibility| Little Moon Stone

Cooperation, Contribution | HorseTeacher18323856316 (Same as WeChat)

 Read the original text, which isPopular Articles